Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04772937 | Comparison of LLETZ Versus LEEP for the Treatment of Cervical Dysplasia | recruiting | N/A | 206 | Ruhr University of BochumOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06800391 | Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in HUGE Pseudomyxoma Peritonei Patients(REVERSE) | recruiting | Phase 2 | 31 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2025 |
| clinicaltrials |
| NCT06800612 | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers | recruiting | — | 100 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04859530 | Automated Cervical Cancer Screening Using a Smartphone-based Artificial Intelligence Classifier | recruiting | N/A | 5,886 | Prof. Patrick PetignatOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT04957511 | Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | recruiting | — | 30 | ViomeINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06800105 | Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study | recruiting | — | 10 | University of Tennessee Graduate School of MedicineOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06392997 | Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology(GynRNA) | recruiting | — | 2,500 | ZIWIGINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05909111 | MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos Therapy: Feasibility Study(Ethos Col) | recruiting | N/A | 15 | Recherche cliniqueOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06785077 | Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors | recruiting | N/A | 157 | European Institute of OncologyOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03624712 | Analysis and Optimization of Predictive and Therapeutic Models in Uterine Neoplasms | recruiting | — | 580 | University Hospital TuebingenOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04846933 | Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC(DECIDER) | recruiting | N/A | 200 | Turku University HospitalOTHER_GOV | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06775470 | Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer | recruiting | — | 300 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06777082 | Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma(OVCAR) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04061967 | Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer. | recruiting | N/A | 20,000 | Karolinska InstitutetOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774209 | Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06774482 | Evaluation of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Uterine Neoplasms | recruiting | — | 3,000 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06307886 | Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator | recruiting | — | 108 | Gaziosmanpasa Research and Education HospitalOTHER_GOV | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06584032 | Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer | recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760923 | Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression | recruiting | — | 240 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06020755 | Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7(TA7) | recruiting | Phase 2 | 17 | Peking Union Medical College HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06751303 | Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's(4PDQ) | recruiting | N/A | 100 | University of SaskatchewanOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05855941 | Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)(PRODIGYN) | recruiting | — | 120 | Region VästerbottenOTHER_GOV | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735326 | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer | recruiting | Phase 2 | 105 | Qilu Hospital of Shandong UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06726291 | Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer(NOEME) | recruiting | Phase 4 | 84 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05655260 | PErsonalized TReatment for Endometrial Carcinoma(PETREC) | recruiting | N/A | 300 | University of HelsinkiOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | recruiting | Phase 2 | 74 | Anhui Provincial Cancer HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06603506 | Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study(PENDOR) | recruiting | — | 16 | Centre Francois BaclesseOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT05927818 | Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06692166 | A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 420 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02754115 | An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 400 | Tata Memorial CentreOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05694208 | The Effect of Mobile-Based Education Given to Patients Undergoing Gynecological Oncology Surgery on Quality of Life | recruiting | N/A | 84 | Istanbul University - CerrahpasaOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial(HPV-VIM) | recruiting | Phase 2 | 85 | Baylor College of MedicineOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06681259 | Clinical Specialty Queue For Gestational Trophoblastic Neoplasia | recruiting | — | 1,000 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06680791 | Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors(MPEC) | recruiting | — | 280 | Lukas VanekOTHER_GOV | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06289062 | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06672497 | Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients | recruiting | — | 30 | University of South CarolinaOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | recruiting | Phase 2 / Phase 3 | 440 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06416748 | Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer(LASH) | recruiting | N/A | 974 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06416150 | Reducing Urban Cervical Cancer Disparities | recruiting | N/A | 546 | Fox Chase Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06656949 | Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer(SLN-EC-01) | recruiting | N/A | 42 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06614790 | Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.(NIRAPARIB) | recruiting | — | 300 | Pomeranian Medical University SzczecinOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06655506 | Enhanced Recovery Protocols in Gynecologic Oncology(ERGO) | recruiting | — | 600 | National and Kapodistrian University of AthensOTHER | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06522828 | A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients | recruiting | Phase 2 | 80 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04921527 | Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer(CHIPRO) | recruiting | Phase 3 | 454 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Oct 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 30, 2025source: clinicaltrials